


Supplementary Information


**Inactivation of the CRISPR-Cas9 ribonucleoprotein complex by AcrIIC2**

Thavalingam et al.



**Supplementary Figure 1: Limited  $\alpha$ -chymotrypsin proteolysis.**



(A) Limited proteolysis of Nme1Cas9 with and without AcrIIC2<sub>Nme</sub>. (B) Nme1Cas9-sgRNA with and without DNA. (C) Nme1Cas9-AcrIIC2<sub>Nme</sub>-sgRNA with and without DNA.




**Supplementary Figure 2: Characterization of the competition of AcrIIc2<sub>Nme</sub> over sgRNA binding to Nme1Cas9 by isothermal titration calorimetry (ITC).**

ITC measurement for the binding affinities of Nme1Cas9 toward AcrIIc2<sub>Nme</sub> (A) and sgRNA (B). ITC measurements for the binding affinities of (Nme1Cas9-AcrIIc2<sub>Nme</sub>) for sgRNA. The molar ratios of Nme1Cas9 over AcrIIc2<sub>Nme</sub> were set to 1:2 (C), 1:10 (D) and 1:20 (E). All ITC measurements were repeated three times with one representative experiment shown.

A




B



**Supplementary Figure 3: Nme1Cas9-sgRNA complex formation is blocked by higher AcrIIc2<sub>Nme</sub> concentrations.**


(A) AcrIIc2<sub>Nme</sub>, sgRNA and Nme1Cas9 were mixed together with the molar ratio of 2:1:1, 3:1:1 or 10:1:1. The small peak indicated by the black arrow is the Nme1Cas9-sgRNA complex. No Nme1Cas9-sgRNA complex is observed when a 10-fold excess of AcrIIc2<sub>Nme</sub> is present. (B) Competitive cleavage assays with various molar ratios of anti-CRISPR reveals that AcrIIc2<sub>Nme</sub> and sgRNA compete for the binding site of Nme1Cas9. Linear plasmid DNA was used as the substrate. The molar ratio of the Nme1Cas9 and AcrIIc2<sub>Nme</sub> are shown above the gel. The molar ratio of Nme1Cas9 and sgRNA is 1:1.1. (i) AcrIIc2<sub>Nme</sub> was mixed with Nme1Cas9 and incubated for 15 min to form the AcrIIc2<sub>Nme</sub>-NmeCas9 complex before addition of sgRNA. (ii) The AcrIIc2<sub>Nme</sub>, sgRNA and Nme1Cas9 were added simultaneously. Nme1Cas9 and sgRNA were added at a ratio of 1:1.1 with a molar ratio of 2 to 40-fold excess of AcrIIc2<sub>Nme</sub>, as noted above the gel.





**Supplementary Figure 4: Structure of AcrIIIC2<sub>Nme</sub>-Nme1Cas9 complex treated by  $\alpha$ -chymotrypsin before crystallization.**

(A) Stereo image of the electron density of PBD 6JDJ. Cartoon representation (B) and surface representation (C) of AcrIIIC2<sub>Nme</sub>-Nme1Cas9 complex.



**Supplementary Figure 5: Gel filtration experiments to assess the ability of AcrIIc2<sub>Nme</sub> mutants to interact with Nme1Cas9.**

First, Nme1Cas9 incubated with AcrIIc2<sub>Nme</sub> mutant protein was purified by gel filtration (blue line) to get the preformed Nme1Cas9-AcrIIc2<sub>Nme</sub> complex. Fractions of the left peak (blue) contain the Nme1Cas9-AcrIIc2<sub>Nme</sub> complex. To test whether the sgRNA replaces the AcrIIc2<sub>Nme</sub> mutant bound to Nme1Cas9, sgRNA was added to the preformed Nme1Cas9-AcrIIc2<sub>Nme</sub> the complex followed by gel filtration (red line). Fractions indicated with yellow or cyan stars were analyzed on SDS-PAGE gel (left panel) and Urea-PAGE gel (right panel). The component of the peak indicated with the yellow star is Nme1Cas9-sgRNA complex, and that with the cyan star is the free sgRNA. (A) AcrIIc2<sub>Nme</sub> E24A mutant, (B) AcrIIc2<sub>Nme</sub> D108A mutant and (C) AcrIIc2<sub>Nme</sub> E17A/E24A mutant.

**Supplementary Table 1. Primers used for construct generation**

Primer	Sequence (5'-3')
NmeCas9_Sumo_F	CGCGGATCCATGGCTGCGTTTAAACCGAAC
NmeCas9_Sumo_R	CCGCTCGAGTTAACGAACCGGCGGGCGTT
AcrIIIC2_Sumo_F	CGCGGATCCATGTCTAAAAACAACATCTTC
AcrIIIC2_Sumo_R	CCGCTCGAGCTAATCATCCCAACCTTCCAG
sgRNA_F	TCACTCTGCTATTTAACTTTAC
sgRNA_R	CCCAAGCTTCGCAAATCGTTT
Cje_F1	TTAAAAAATGACTCGAGTAAGGATCTCCAG
Cje_R1	GGATAAAAATGCTATGGCATAGCAAAGTG
Cje_F2	ATGCCATAGCATTTTTATCCATAAGATTAGCGG
Cje_R2	CTCTGAAAACGAAAAACCGCCTTGCGAG
Cje_F3	CGGTTTTTTCGTTTTCAGAGCAAGAGATTACG
Cje_R3	TTCTTGCCATAGATCCTTTCTCCTCTTTAGATC
Cje_F4	GAAAGGATCTATGGCAAGAATTTTGGCATTG
Cje_R4	CTTACTCGAGTCATTTTTTAAAATCTTCTCTTTGTCTAAAC
Cje Mu targeting_F	TCCATGTTGCTAAAAAGCAAGGATGGG
Cje Mu targeting_R	ACAACCCATCCTTGCTTTTTAGCAACA
Nme1_F1	CTCGAGTAAGGATCTCCAGGCATC
Nme1_R1	GAGACCTGCCGTGGTCTCATG CTGTTTCTCCATGAGACCACGGCAGGTCTCGTTGTAGCTCCCTTTCTCA TTTCG
Nme1_F2	TTTGATGCCTGGCAGTAAACGATGCCCTTAAAGCAG
Nme1_R2	AAGGGGCATCGTTTACTGCCAGGCATCAAATAAAACG
Nme1_F3	TTTGAAGGCAGCCATAGATCCTTTCTCCTCTTTAGATCTTTTGAATTC
Nme1_R3	GAGGAGAAAGGATCTATGGCTGCCTTCAAACCTAATTC
Nme1_F4	GTAATGATCTCCGTAGATTTCCGGCGCAGGCTTCATC
Nme1_R4	GCCTGCGCCGAAATCTACGGAGATCATTACGGCAAGAAGAATACGG
Nme1_F5	TGACAGTCTCCATATGCCCTTGCCCGCTCATCTTCC
Nme1_R5	TGAGCGGGCAAGGGCATATGGGAGACTGTCAAATCCGCCAAAC
Nme1_F6	TTATTTGATGCCTGGAGATCCTTACTCGAGTTAACGGACAGGGCGGGCG
Nme1_R6	TTTTTTC
Nme Mu targeting_F	TCCACATCTGGTTCAGCTCTTCAATCAG
Nme Mu targeting_R	ACAACCTGATTGAAGAGCTGGAACCAGATG
Hpa_F1	ATTGGAAGTGGATAACTCGAGTAAGGATCTCCAG CCAAGGTTCGAGTCCAAGGATATAATGTAAGTTTTTATTTTCCATAGATC CTTTCTCCTCTTTAGATC
Hpa_R1	GATCTAAAGAGGAGAAAGGATCTATGGAAAATAAAAACTTACATTAT ATCCCTTGGACTIONGACCTTGG
Hpa_F2	AGATCCTTACTCGAGTTATCCACTTCCAATGTTACG
Hpa_R2	GTTTTTCAGAGCAAGAGATTACGCGCAGACCAAAAACG
Hpa_F3	GCTATGGCATAGCAAAGTGTGACG
Hpa_R3	
Hpa Mu targeting_F	TCCACTGGTTTGCCGAAAACATCGGCTGG
Hpa Mu targeting_R	ACAACCAGCCGATGTTTTCGGCAAACCAG
pMCSG7 Gib F	AACATTGGAAGTGGATAACGGATC
pMCSG7 Gib R	GGCATTGGATTGGAAGTACAGGTTCC
HpaCas9 HNH Gib F	GAACCTGTACTIONTCCAATCCAATGCCCGTGACTIONTAGAAAAACGTC GGATCCGTTATCCACTTCCAATGTTTTATAAATTACGTTCAATAAAGCC C
HpaCas9 HNH Gib R	C

HpaCas9 PID Gib F	GAACCTGTACTTCCAATCCAATGCCAATCATGAATTTGTCCAACCTCTG
HpaCas9 PID Gib R	TCGGATCCGTTATCCACTTCCAATG
HpaCas9 RECD $\Delta$ BH Gib F	GAACCTGTACTTCCAATCCAATGCCGCTCGTCTGAAAAAAGC
HpaCas9 RECD $\Delta$ BH Gib R	GGATCCGTTATCCACTTCCAATGTTTTAATGGTTTTCTTCTGTTTTTTTA
HpaCas9 REC Gib F	C
pMCSG7 mid Gib1 F	GAACCTGTACTTCCAATCCAATGCCGCGCTTTTCTCGCC
pMCSG7 mid Gib2 R	CTGATTCTGTGGATAACCGTATTACCGCC
HpaCas9 $\Delta$ HNH Gib1 R	CGGTAATACGGTTATCCACAGAATCAGG
HpaCas9 $\Delta$ HNH Gib2 F	GCGTATCATTACGATCTTTGTAAGATTTGCCAAC
HpaCas9 $\Delta$ PID Gib F	ATCTTACAAAGATCGTAATGATACGCGCTACGTTGCTC
HpaCas9 $\Delta$ PID Gib R	GAACCTGTACTTCCAATCCAATGCCATGGAAAATAAAAAAC
HpaCas9 $\Delta$ REC Gib1 R	GTTATCCACTTCCAATGTTTTAGGCTTGTGGACGATCCG
HpaCas9 $\Delta$ REC Gib2 F	TGTGGTAAAGAAGTGAAACGCGACGTTGAGTTAATCGACG
AcrIIC2_E17A_F	ACTCAACGTCGCGTTCCTTACCACAGATTCCAGCTG
AcrIIC2_E17A_R	ACCCGACCATCATCCACGGTGCGGCGCGTGGTGGAAAACGAT
AcrIIC2_E17D_F	ATCGTTTTTACCACGCGCCGCACCGTGGATGATGGTTCGGGT
AcrIIC2_E17D_R	ACCCGACCATCATCCACGGTGACGCGCGTGGTGGAAAACGATGA
AcrIIC2_E24A_F	TCATCGTTTTTACCACGCGCGTCACCGTGGATGATGGTTCGGGT
AcrIIC2_E24A_R	GCGCGTGGTGGAAAACGATGCGTTTCGTTGTTACACCCCGTTA
AcrIIC2_E24D_F	TAACGGGTGTGAACAACGAACGCATCGTTTTTACCACGCGC
AcrIIC2_E24D_R	AAGCGCGTGGTGGAAAACGATGACTTCGTTGTTACACCCCGTTA
AcrIIC2_D108A_F	TAACGGGTGTGAACAACGAAGTCATCGTTTTTACCACGCGCTT
AcrIIC2_D108A_R	GTGATCGTATCGCGCGGATGCGCTGATGCTGAACGAAGATGC
AcrIIC2_D108E_F	GCATCTTCGTTTCAGCATCAGCGCATCCGCCGCGATACGATCAC
AcrIIC2_D108E_R	GTGATCGTATCGCGCGGATGAACTGATGCTGAACGAAGATGC
AcrIIC2_N112A_F	GCATCTTCGTTTCAGCATCAGTTTCATCCGCCGCGATACGATCAC
AcrIIC2_N112A_R	CGGCCGATGATCTGATGCTGGCGGAAGATGCGGCTGATCTGGA
Nme1Cas9_R62A_F	TCCAGATCAGCCGCATCTTCCGCCAGCATCAGATCATCCGCCG
Nme1Cas9_R62A_R	GTGATAGCCTGGCTATGGCAGCGCGCTTAGCGCGCTCTGTA
Nme1Cas9_R62K_F	TACAGAGCGCGCTAAGCGCGCTGCCATAGCCAGGCTATCAC
Nme1Cas9_R62K_R	GTGATAGCCTGGCTATGGCAAACGCTTAGCGCGCTCTGTACG
Nme1Cas9_R66A_F	CGTACAGAGCGCGCTAAGCGTTTTGCCATAGCCAGGCTATCAC
Nme1Cas9_R66A_R	CTATGGCACGTCGCTTAGCGGCGTCTGTACGTCGTCTGACTCG
Nme1Cas9-R69A-F	CGAGTCAGACGACGTACAGACGCCGCTAAGCGACGTGCCATAG
Nme1Cas9-R69A-R	CGCTTAGCGCGCTCTGTAGCGCGTCTGACTCGTCGTCGCGC
Nme1Cas9_R70A_F	GCGCGACGACGAGTCAGACGCGCTACAGAGCGCGCTAAGCG
Nme1Cas9_R70A_R	GCTTAGCGCGCTCTGTACGTGCGCTGACTCGTCGTCGCGCGCA
Nme1Cas9_R69A_R70A_F	TGCGCGCGACGACGAGTCAGCGCACGTACAGAGCGCGCTAAGC
Nme1Cas9_R69A_R70A_R	GTCGCTTAGCGCGCTCTGTAGCGGCGCTGACTCGTCGTCGCGCGCA
Nme1Cas9_R73A_F	TGCGCGCGACGACGAGTCAGCGCCGCTACAGAGCGCGCTAAGCGAC
Nme1Cas9_R73A_R	GCTCTGTACGTCGTCTGACTGCGCGTCGCGCGCACCGTCTGCT
Nme1Cas9_R74A_F	AGCAGACGGTGC GCGGACGCGCAGTCAGACGACGTACAGAGC
Nme1Cas9_R74A_R	CTGTACGTCGTCTGACTCGTGC GCGCGCGCACCGTCTGCTGCG
Nme1Cas9_R74K_F	CGCAGCAGACGGTGC GCGCGCGCACGAGTCAGACGACGTACAG
Nme1Cas9_R74K_R	CTGTACGTCGTCTGACTCGTAAACGCGCGCACCGTCTGCTGCG
Cje_sgRNA	CGCAGCAGACGGTGC GCGCGGTTTTACGAGTCAGACGACGTACAG
Nme_sgRNA	GUUUUAGUCCCUGAAAAGGGACUAAAAUAAAGAGUUUGCGGGACUC
	UGC GGGGUUACAAUCCCCUAAAACCGCUUUUUU
	GUUGUAGCUCUUUCUCAUUUCGGAAACGAAAUGAGAACCGU
	UGC UACAAUAAGGCCGUCUGAAAAGAUGUGCCGCAACGCUCUGCCCC

---

UAAAAGCUUCUGCUUUAAAGGGGCAUCGUUUA

Hpa\_sgRNA

GUUGUAGCUCCCUUUUUCAUUUCGCAGAAAUGCGAAAUGAAAAACG  
UUGUUACAAUAAGAGAAAAGAUUUCUCGCAAAGCUCUGUCCCUUGA  
AAUGUAAGUUUCAAGGGACAUCUUUU

---